Market
Additive Manufacturing Adhesives & Sealants Aerospace Agriculture Animal Nutrition & Health Automotive & Transportation Battery Building, Construction & Infrastructure Catalysts Chemical Industry Circular Economy Coatings, Paints & Printing Composites Consumer Goods & Lifestyle Electronics & Telecommunications Energy, Environment & Utilities Food & Beverage Green Hydrogen Home Care & Cleaning Industrial Manufacturing & Machinery Lubricants & Lubricant Additives Medical Devices Metals & Mining Oil & Gas, Petrochemicals Personal Care & Beauty Pharma & Biopharma Plastics & Rubber Pulp, Paper & Packaging Textiles, Leather & Nonwovens
About Evonik
What drives us
We go beyond Purpose Innovation Circularity BVB Partnership History
Structure & Organization
Executive Board Supervisory Board Segments Business Lines ESHQ Procurement Governance & Compliance Facts & Figures General Conditions of Sale and Delivery (GTC)
Business Lines Career Investor Relations
SHARE
Press Release
Back
Products

May 14, 2024

Evonik presents nutraceutical innovations at Vitafoods Europe 2024

  • New concept: AvailOm® omega-3 powder & Boswellia for joint health
  • New study results: IN VIVO BIOTICS™ synbiotic solutions
  • Next Generation Solutions: European-made, evidence-based food ingredients available to food supplement brands

Evonik is presenting its latest nutraceutical ingredient innovations at Vitafoods Europe 2024 in Geneva, Switzerland. With the new concept of AvailOm® & Boswellia for joint health, the latest study results on IN VIVO BIOTICS™ and the expansion of the Healthberry® portfolio to the U.S. market, the company provides advanced, evidence-based food ingredients to boost consumer preferences and differentiate functional food and food supplement brands.

The nutraceuticals portfolio at Evonik Health Care includes naturally occurring ingredients with scientifically proven health benefits, as well as nutraceutical coating technologies that help ensure the health ingredients are released in the human body at the right time and location. As part of the life sciences division, Nutrition & Care, Evonik Health Care has centred its business on improving health and quality of life. Customers benefit from a tailored offering of ingredients, as well as application and formulation expertise as a system solution.

"Through our dedication to research and innovation, we provide customized nutra ingredients that address unique health requirements, enabling our partners to offer their customers a convenient and elevated nutritional experience that enhances their quality of life," said Susanne Pluta, Director of Consumer Products at Evonik Health Care.   

Key highlights at Vitafoods Europe 2024:

  • AvailOm® omega-3 powder and Boswellia serrata ingredient concept. This unique combination is targeted for joint health applications. Its efficacy and synergistic mechanism have been proven through in vitro and human intervention studies. The concept combines Evonik’s superior formulation expertise and scientific evidence for efficacy.
  • IN VIVO BIOTICS™ concepts. A recent study showed the superior gluten-degrading efficacy of IN VIVO BIOTICS™ gluten tolerance, also in comparison to conventional enzyme-based gluten digestion aids.
  • Expansion of Healthberry® 865/900 to the U.S. market. With the FDA registration of Evonik’s Norwegian facility Medpalett, Healthberry® is now sold in bulk to dietary supplement companies with formulation capabilities and partners in the U.S. for further development and commercialization.

To learn more about Evonik’s innovative portfolio of nutraceutical solutions visit Booth E162 at Vitafoods Europe 2024.

For more information about Evonik at Vitafoods Europe 2024 click here.

Evonik: Leading beyond chemistry

Evonik goes beyond the boundaries of chemistry with its combination of innovative strength and leading technological expertise. The global chemical company, headquartered in Essen, Germany, is active in more than 100 countries and generated sales of €15.2 billion and earnings (adjusted EBITDA) of €2.1 billion in 2024. The common motivation of the approximately 32,000 employees: to provide customers with a decisive competitive advantage with tailor-made products and solutions as a superforce for industry, thereby improving people's lives. In all markets. Every day.

About Nutrition & Care

The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of €3.76 billion in 2024 with more than 5,500 employees.  

Disclaimer

In so far as forecasts or expectations are expressed in this release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.